SCL Science Inc. Share Price

Equities

A246960

KR7246960009

Pharmaceuticals

End-of-day quote Korea S.E. 23:00:00 25/06/2024 BST 5-day change 1st Jan Change
9,500 KRW -4.04% Intraday chart for SCL Science Inc. -6.22% +7.10%

Financials

Sales 2022 370M 265K 21.05M Sales 2023 1.32B 949K 75.27M Capitalization 64.19B 46.09M 3.65B
Net income 2022 -5.97B -4.29M -340M Net income 2023 -5.03B -3.61M -286M EV / Sales 2022 150 x
Net Debt 2022 7.42B 5.33M 423M Net cash position 2023 1.05B 757K 60.06M EV / Sales 2023 47.8 x
P/E ratio 2022
-7.57 x
P/E ratio 2023
-11.1 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 53.14%
More Fundamentals * Assessed data
Dynamic Chart
H2U Corp. announced that it has received KRW 1.29506497 billion in funding from InnoTherapy, Inc. CI
H2U Corp. announced that it has received KRW 1.2171 billion in funding from InnoTherapy, Inc. CI
InnoTherapy, Inc. announced that it has received KRW 5.9999961 billion in funding from Scl Holdings and another investor CI
Health to U Corporation announced that it has received funding from InnoTherapy, Inc. CI
H2U Corp. announced that it expects to receive KRW 1.2171 billion in funding from InnoTherapy, Inc. CI
InnoTherapy, Inc. announced that it expects to receive KRW 5.9999961 billion in funding CI
PhAST Corp. announced that it has received KRW 1.30609774 billion in funding from InnoTherapy, Inc. CI
Lee Moon Su completed the acquisition of a 98.04% stake in NVC 2019 Bio Health Care Investment Association from InnoTherapy, Inc. CI
Lee Moon Su agreed to acquire 98.039216% stake in NVC 2019 Bio Health Care Investment Association from InnoTherapy, Inc. for approximately KRW5 billion. CI
PhAST Corp. announced that it expects to receive KRW 1.30609774 billion in funding from InnoTherapy, Inc. CI
InnoTherapy, Inc. announced that it has received KRW 4.999995 billion in funding from SCL Healthcare Co., Ltd., Seoul Clinical Laboratories CI
InnoTherapy, Inc. announced that it expects to receive KRW 4.999995 billion in funding from SCL Healthcare Co., Ltd., Seoul Clinical Laboratories CI
SCL Healthcare Co., Ltd. completed the acquisition of 22.97% stake in InnoTherapy, Inc. from Lee, Moon Soo. CI
SCL Healthcare Co., Ltd. agreed to acquire 22.97% stake in InnoTherapy, Inc. from Lee, Moon Soo for KRW 21.8 billion. CI
InnoTherapy, Inc. announced that it has received KRW 14.999868397 billion in funding from a group of investors CI
More news
1 day-4.04%
1 week-6.22%
Current month-8.39%
1 month-7.77%
3 months+4.63%
6 months+9.20%
Current year+7.10%
More quotes
1 week
9 500.00
Extreme 9500
10 550.00
1 month
9 500.00
Extreme 9500
11 850.00
Current year
7 600.00
Extreme 7600
11 850.00
1 year
7 200.00
Extreme 7200
11 850.00
3 years
6 660.00
Extreme 6660
20 900.00
5 years
5 200.00
Extreme 5200
27 800.00
10 years
5 200.00
Extreme 5200
27 800.00
More quotes
Managers TitleAgeSince
Founder 50 18/04/10
Director of Finance/CFO 57 -
Chief Tech/Sci/R&D Officer 48 -
Members of the board TitleAgeSince
Director of Finance/CFO 57 -
Founder 50 18/04/10
Chief Tech/Sci/R&D Officer 48 -
More insiders
Date Price Change Volume
25/06/24 9,500 -4.04% 13 930
25/06/24 9,900 -2.17% 13,360
24/06/24 10,120 -0.88% 4,245
21/06/24 10,210 -1.26% 5,107
20/06/24 10,340 +0.88% 2,706

End-of-day quote Korea S.E., June 25, 2024

More quotes
SCL Science Inc, formerly InnoTherapy Inc, is a Korea-based company principally engaged in the research, development, manufacture, export and sale of medical hemostatic agents. The main developed products include medical hemostats and sealants with biomimetic technology. In addition, the Company is engaged in the bio-logistics business.
More about the company
  1. Stock Market
  2. Equities
  3. A246960 Stock